JD Supra

AIM Feedback Statement: Immediate Changes and Next Steps

Following its April 2025 Discussion Paper, “Shaping the Future of AIM", the London Stock Exchange (the Exchange) has published a feedback statement outlining its roadmap for AIM. This plan combines ...
Business Wire

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange ...
Seeking Alpha

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for ...

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The ...
Business Wire

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company has filed its Definitive Proxy Statement in connection with AIM’s ...
Nasdaq

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Thank you for your investment in AIM ImmunoTech (“AIM” or the “Company”). We remain deeply committed to our mission of serving patients and delivering value for you, our shareholders. We are excited ...